阿普托尔用于接受血管内治疗的缺血性卒中患者的安全性和有效性:一项1/2期随机临床试验
该1b/2a期双盲随机安慰剂对照试验在西班牙和法国的15个中心纳入139例大血管闭塞缺血性卒中患者,评估阿普托尔联合血管内治疗的安全性。0.2 mg/kg 阿普托尔组主要终点事件发生率低于安慰剂组(14% vs 29%),且72小时美国国立卫生研究院卒中量表评分和90天残疾程度更优。作者认为0.2 mg/kg 阿普托尔安全并可能具有临床获益,但需更大规模的确证性试验验证。
要点
- 0.2 mg/kg 阿普托尔组主要安全终点事件发生率为14%,安慰剂组为29%。
- 0.2 mg/kg 阿普托尔组90天良好结局的common OR为2.44(95%CI 1.76-5.00)。
- 0.2 mg/kg 阿普托尔组72小时NIHSS评分较安慰剂组降低45%(95%CI -67%至-10%)。
核心结论
- 在急性缺血性卒中发病6小时内,0.2 mg/kg 阿普托尔联合血管内治疗是安全的,并与潜在的有意义的临床效应相关,较安慰剂降低90天死亡率和残疾。
- 这些初步发现有待更大规模的关键试验确认。
研究设计与样本
- 本研究为1b/2a期双盲、随机、安慰剂对照研究,在西班牙和法国的15个中心于2020年至2022年开展。
- 纳入年龄18至90岁、因大血管闭塞导致缺血性卒中且在发病6小时内就诊的患者,其他标准包括Alberta卒中项目早期CT评分6至10分、基线CT灌注估计梗死核心体积5至70 mL、计划接受血管内治疗。
- 研究期间共有4174例患者接受了血管内治疗。
- 1b期:0.025、0.05、0.1或0.2 mg/kg 阿普托尔或安慰剂;2a期:0.05或0.2 mg/kg 阿普托尔或安慰剂;两期均联合血管内治疗及必要时静脉溶栓。
- 1b期32例患者均匀分配至4个剂量组;完成后无安全性担忧,选择2个剂量进入2a期,119例患者按1:1:√2比例随机分配至阿普托尔0.05 mg/kg组(n=36)、阿普托尔0.2 mg/kg组(n=36)或安慰剂组(n=47)。
主要发现
- 主要终点在安慰剂组55例中发生16例(29%),包括死亡10例(18.2%)、症状性颅内出血4例(7.3%)、恶性卒中4例(7.3%)和复发性卒中2例(3.6%)。
- 主要终点在阿普托尔0.05 mg/kg组42例中发生15例(36%),包括死亡11例(26.2%)、症状性颅内出血3例(7.2%)、恶性卒中2例(4.8%)和复发性卒中2例(4.8%)。
- 主要终点在阿普托尔0.2 mg/kg组42例中发生6例(14%),包括死亡2例(4.8%)、症状性颅内出血2例(4.8%)和复发性卒中3例(7.1%)。
- 阿普托尔0.2 mg/kg组72小时NIHSS评分较安慰剂组降低(对数转换后平均差异-45%;95%CI -67%至-10%)。
- 阿普托尔0.2 mg/kg组最终梗死体积较安慰剂组缩小(对数转换后平均差异-42%;95%CI -66%至1%),90天残疾程度更低(良好结局的common OR为2.44;95%CI 1.76至5.00)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些初步发现有待更大规模的关键试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: ApTOLL is a TLR4 antagonist with proven preclinical neuroprotective effect and a safe profile in healthy volunteers. OBJECTIVE: To assess the safety and efficacy of ApTOLL in combination with endovascular treatment (EVT) for patients with ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: This phase 1b/2a, double-blind, randomized, placebo-controlled study was conducted at 15 sites in Spain and France from 2020 to 2022. Participants included patients aged 18 to 90 years who had ischemic stroke due to large vessel occlusion and were seen within 6 hours after stroke onset; other criteria were an Alberta Stroke Program Early CT Score of 6 to 10, estimated infarct core volume on baseline computed tomography perfusion of 5 to 70 mL, and the intention to undergo EVT. During the study period, 4174 patients underwent EVT. INTERVENTIONS: In phase 1b, 0.025, 0.05, 0.1, or 0.2 mg/kg of ApTOLL or placebo; in phase 2a, 0.05 or 0.2 mg/kg of ApTOLL or placebo; and in both phases, treatment with EVT and intravenous thrombolysis if indicated. MAIN OUTCOMES AND MEASURES: The primary end point was the safety of ApTOLL based on death, symptomatic intracranial hemorrhage (sICH), malignant stroke, and recurrent stroke. Secondary efficacy end points included final infarct volume (via MRI at 72 hours), NIHSS score at 72 hours, and disability at 90 days (modified Rankin Scale [mRS] score). RESULTS: In phase Ib, 32 patients were allocated evenly to the 4 dose groups. After phase 1b was completed with no safety concerns, 2 doses were selected for phase 2a; these 119 patients were randomized to receive ApTOLL, 0.05 mg/kg (n = 36); ApTOLL, 0.2 mg/kg (n = 36), or placebo (n = 47) in a 1:1:√2 ratio. The pooled population of 139 patients had a mean (SD) age of 70 (12) years, 81 patients (58%) were male, and 58 (42%) were female. The primary end point occurred in 16 of 55 patients (29%) receiving placebo (10 deaths [18.2%], 4 sICH [7.3%], 4 malignant strokes [7.3%], and 2 recurrent strokes [3.6%]); in 15 of 42 patients (36%) receiving ApTOLL, 0.05 mg/kg (11 deaths [26.2%], 3 sICH [7.2%], 2 malignant strokes [4.8%], and 2 recurrent strokes [4.8%]); and in 6 of 42 patients (14%) receiving ApTOLL, 0.2 mg/kg (2 deaths [4.8%], 2 sICH [4.8%], and 3 recurrent strokes [7.1%]). ApTOLL, 0.2 mg/kg, was associated with lower NIHSS score at 72 hours (mean difference log-transformed vs placebo, -45%; 95% CI, -67% to -10%), smaller final infarct volume (mean difference log-transformed vs placebo, -42%; 95% CI, -66% to 1%), and lower degrees of disability at 90 days (common odds ratio for a better outcome vs placebo, 2.44; 95% CI, 1.76 to 5.00). CONCLUSIONS AND RELEVANCE: In acute ischemic stroke, 0.2 mg/kg of ApTOLL administered within 6 hours of onset in combination with EVT was safe and associated with a potential meaningful clinical effect, reducing mortality and disability at 90 days compared with placebo. These preliminary findings await confirmation from larger pivotal trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04734548.
引用
- Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37338893. doi:10.1001/jamaneurol.2023.1660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。